Threshold Pharmaceuticals, Inc (THLD): Opiniones

Uff, está que tira la casa por la ventana. ¡Será manirroto el tío!? jajaja

Nipun Davar, Threshold Pharmaceuticals's Vice President, recently acquired 3,000 shares of the company. The buys took place at $2.98 per share, on October 13, 2014. Davar now owns 3,000 shares of the company.

http://www.conferencecalltranscripts.org/summary2/?id=1201493

Seguimos viendo los 2.90 desde arriba, algo es algo. El que no se consuela................:))

Y se queda tan ancho con esa supercompra, jajaja

http://www.thelifesciencesreport.com/pub/co/4663

Thld anuncia nueva fase 1/2 datos sobre TH-302 en Glioblastoma a ser presentado en la reunión anual de 2014

http://boardvote.com/symbol/THLD/communique/800003

Reportaron cuentas tb,luego las leere,tengo que ir al curro!

Threshold Pharma (THLD) Misses Q3 EPS by 3c
Threshold Pharma (NASDAQ: THLD) reported Q3 EPS of ($0.15), $0.03 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $3.82 million.
For earnings history and earnings-related data on Threshold Pharma (THLD)